ARK Genomic Revolution ETF (ARKG)

Delayed Data
As of Oct 25
 +1.01 / +1.35%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.


1 month-7.28% 3 years+41.04%
3 months-13.04% 5 years+35.38%
1 year+9.09% Since inception+22.07%
Data through 10/23/2021

Quote Details

Previous close$74.81
Open day’s range74.14 – 76.20
Net asset value (NAV)74.87 (10/22/2021)
Daily volume2,023,613
Average volume (3 months)2,214,087
Data as of 6:31pm ET, 10/25/2021

Peer Comparisonvs. Health ETFs

Performance 5-yr return+35.38%+13.75%
Expense Gross exp ratio0.75%1.01%
Risk 5 year sharpe ratio0.940.74
Net assets$7.1B$2.4B
Average market cap$7.2B$34.7B
Average P/E--25.1
Dividend / Share--0.25%


IEHS iShares Evolved U.S. Healthcare Staples ...
RYH Invesco S&P 500® Equal Weight Health Ca...
VHT Vanguard Health Care Index Fund ETF Shar...


Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
TDOC Teladoc Health Inc6.90%
EXAS Exact Sciences Corp5.24%
PACB Pacific Biosciences of California Inc4.93%
VRTX Vertex Pharmaceuticals Inc4.32%
IONS Ionis Pharmaceuticals Inc3.98%
FATE Fate Therapeutics Inc3.95%
REGN Regeneron Pharmaceuticals3.60%
TWST Twist Bioscience Corp3.29%
TAK Takeda Pharmaceutical3.08%
ACCD Accolade Inc3.07%